Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKD-703 in Advanced c-Met Expressing Solid Tumors and NSCLC
NCT07439094Phase 2Recruiting
- Sponsor
- Chong Kun Dang Holdings
- Start
- Apr 2026
- Primary completion
- Dec 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of CKD-703 in solid tumor, non-small cell lung cancer (NSCLC), sponsored by Chong Kun Dang Holdings. Started Apr 2026; status: recruiting.
02
Drugs
CKD-703
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07439094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07439094.